Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 12/20 | 0.45 |
| ▸ | KMO | O15229 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14902605 | 0.83 | SYK (0.42) | SYK | |
| SCHEMBL1550203 | 0.82 | SYK (0.50) | SYK | |
| SCHEMBL12385920 | 0.80 | METAP1 (0.45) | PKMSYKKMO | |
| SCHEMBL14902608 | 0.79 | MAPK1 (0.47) | NPC1MAPTTSHRRAB9ASYK | |
| SCHEMBL524226 | 0.78 | SYK (0.55) | MEN1KMT2ASYK | |
| SCHEMBL22201437 | 0.78 | PRKCH (0.56) | NPC1MAPTSYK | |
| SCHEMBL12385958 | 0.78 | METAP1 (0.47) | NPC1MAPTRAB9ASYK | |
| SCHEMBL3280663 | 0.78 | SYK (0.71) | NPC1TP53MAPTRAB9ASYK | |
| SCHEMBL3280853 | 0.78 | SYK (0.73) | SYK | |
| SCHEMBL27915294 | 0.77 | ALK (0.45) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | KARUS THERAPEUTICS LIMITED (UK) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109688-A1 | Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease | PIK3R5, PIK3CA, NFKBIA | MEN1 1168/4885NPC1 479/4885TP53 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.